TITLE

ENCOURAGING RESULTS FROM RHEUMATOID ARTHRITIS STUDY

PUB. DATE
December 2000
SOURCE
Worldwide Biotech;Dec2000, Vol. 12 Issue 12, p6
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Focuses on the results of a clinical study conducted by Angiotech Pharmaceuticals Inc. which used Micellar Paclitaxel for the treatment of patients with rheumatoid arthritis. Reports that Vancouver, British Columbia-based Angiotech Pharmaceuticals, Inc. has announced results from its Phase 1 clinical study using the cancer drug Micellar Paclitaxel for the treatment of patients with rheumatoid arthritis. Methods; Results; Conclusion that the drug was safe and well-tolerated in all patients enrolled in the Phase 1 study.
ACCESSION #
3905753

 

Related Articles

  • Angiotech Pharmaceuticals files for bankruptcy protection.  // Medical Device Daily;1/31/2011, Vol. 15 Issue 20, p4 

    The article unveils the plan of Angiotech Pharmaceuticals to file for bankruptcy protection under the Companies' Creditors Arrangement Act of Canada.

  • Financings Roundup.  // BioWorld Today;2/10/2011, Vol. 22 Issue 28, p2 

    The article reports on the agreement reached by Vancouver, British Columbia-based Angiotech Pharmaceuticals Inc. with the stockholders to extend deadlines outlined in a recapitalization support deal signed on October 29, 2010.

  • Guarded surgical knives designed to maintain sharpness over time. Groves, Nancy; Woodard, Lawrence // Ophthalmology Times;10/15/2008, Vol. 33 Issue 20, p41 

    The article evaluates the new guarded surgical knives from Angiotech.

  • Financings roundup.  // Medical Device Daily;4/26/2011, Vol. 15 Issue 80, p6 

    The article reports that Angiotech Pharmaceuticals will extend the maturity of the outstanding amount of its 7.75% senior subordinated notes.

  • Infections differ in two groups for 2 trials of Vascular Wrap.  // Medical Device Daily;4/22/2008, Vol. 12 Issue 78, p2 

    The article reports that Angiotech Pharmaceuticals in April 2008 has suspended enrollments in the clinical trials for its Vascular Wrap device for hemodialysis in the U.S. and Europe. The move follows a report from the company's Data Safety Monitoring Board (DSMB), which reveals an imbalance of...

  • Agreements/contracts.  // Medical Device Daily;6/7/2012, Vol. 16 Issue 108, p3 

    The article reports on an agreement awarded by the Premier Healthcare Alliance to Angiotech for a knotless tissue closure device.

  • Haemacure sells assets to Angiotech Pharma.  // Medical Device Daily;3/23/2010, Vol. 14 Issue 55, p6 

    The article reports on the authorization obtained by Haemacure from the Superior Court of the Province of Quebec to sell its assets to Angiotech Pharmaceuticals, a secured creditor of the company.

  • FACTS & FIGURES.  // Westchester County Business Journal;11/29/2010, Vol. 46 Issue 48, p35 

    The article lists Chapter 11 and corporate reorganizations filed by companies at the U.S. Bankruptcy Court in the Southern District of New York including Angiotech Pharmaceuticals (US) Inc., Cohen & Slamowitz LLP and American Media Operations Inc.

  • Earnings Roundup.  // BioWorld Today;10/22/2007, Vol. 18 Issue 205, p4 

    The article reports on Angiotech Pharmaceuticals Inc.'s third-quarter 2007 earnings. The Vancouver, British Columbia-based company announced total revenues of $68 million, down from $86 million in the same period in 2006, and said it expected to post a net loss. Angiotech's shares also fell and...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics